This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

AAI files amicus in Nexium pay-for-delay appeal supporting class certification

( June 26, 2014, 20:53 GMT | Official Statement) -- MLex Summary: The American Antitrust Institute has filed an amicus brief in the appeal of a lower court’s order granting certification to plaintiffs bringing claims that AstraZeneca entered into anticompetitive agreements to delay entry of a generic version of Nexium. The AAI says that it is possible for common issues to predominate in a case, even if it is difficult to discern if all members suffered injury, and “imposing a requirement of harm to every class member would greatly undermine the primary purpose of antitrust litigation.”...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections